DLL3 is an emerging therapeutic target in small cell lung cancer and other neuroendocrine carcinomas, with 1 FDA-approved therapy and several others under investigation.
Aubrey R. Lasko, PharmD, BCOP
Advertisement
Articles by Aubrey R. Lasko, PharmD, BCOP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
The Controversial 340B Rebate Pilot Program Is Moving Forward
2
Exercise Program Manages Persistent Symptoms Post-COVID-19 Infection
3
FDA Approves IsoPSA Blood Test to Detect Prostate Cancer
4
Cardiometabolic and Psychiatric Risks Converge as Heart–Mind Connection Sharpens
5
